Clinical Trial Update: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease [Phase 3]

View source ↗

Summary

Clinical trial update indicating a Phase 3 study evaluating Rovadicitinib for moderate-to-severe chronic graft-versus-host disease, with recruitment ongoing and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Rovadicitinib (rovadicitinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Graft-versus-host Disease | Phase 3 | Status: RECRUITING